nach oben

Erschienen in:

01.06.2013 | Original article

Interstitial hyperthermia of the prostate in combination with brachytherapy

An evaluation of feasibility and early tolerance

verfasst von: A.M. Kukiełka, M.D., M. Hetnał, M.D., P. Brandys, M.D., T. Walasek, M.D., T. Dąbrowski, M.D., E. Pluta, M.D., D. Nahajowski, R. Kudzia

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 6/2013

Einloggen, um Zugang zu erhalten

Abstract

Objective

A retrospective study to evaluate the feasibility and toxicity of interstitial hyperthermia (IHT) combined with high-dose-rate (HDR) brachytherapy as the initial treatment for low- and intermediate-risk prostate cancer, and as a salvage therapy in previously irradiated patients with local recurrence.

Patients and methods

Between 18 December 2008 and 5 September 2012, 73 prostate cancer patients were treated with interstitial HDR brachytherapy of the prostate combined with IHT. In 54 patients this was the initial therapy for prostate cancer, while the other 19 were treated for local recurrence after previously undergoing external beam radiotherapy (EBRT). Toxicity for the organs of the genitourinary system and rectum was assessed according to the Common Terminology Criteria for Adverse Events (CTCAE) v. 4.03 within 3 months after treatment.

Results

Median follow-up was 15 months (range 3–46). The combination of HDR brachytherapy and IHT was well tolerated. The toxicity profile was similar to that of HDR brachytherapy when not combined with hyperthermia. The most common minor complications were urinary frequency (grade 1: 37 %; grade 2: 22 %), nocturia (three times per night: 29 %; four- or more times per night: 20 %) and transient weakening of the urine stream (grade 1: 36 %; grade 2: 11 %). No early rectal complications were observed in the patient group and the severity of genitourinary toxicity was only grade 1–2.

Conclusion

Early tolerance of IHT in combination with HDR brachytherapy is good. Further prospective clinical studies should focus on the effects of combining IHT with HDR brachytherapy and the influence of this adjuvant therapy on biochemical disease-free survival, local control and overall survival.

Krumholtz JS, Andriole GL (1999) The surgery of prostate cancer: an update of contemporary radical prostatectomy and brachytherapy series. Semin Surg Oncol 17(3):213–218PubMedCrossRef

D’Amico AV, Whittington R, Malkowicz SB et al (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280(11):969–974CrossRef

Pisansky TM, Thames HD, Levy LB et al (2004) Clinical outcomes and prognostic factors in 4,839 patients treated with external radiotherapy for stage T1-T2 prostate cancer [abstract 63]. Proceedings of the annual ASTRO meeting, Int J Radiat Oncol Biol Phys 60:S167

Zagars GK, Pollack A, Smith LG (1999) Conventional external-beam radiation therapy alone or with androgen ablation for clinical stage III (T3, NX/N0, M0) adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 44(4):809–819PubMedCrossRef

Shipley WU, Thames HD, Sandler HM et al (1999) Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 281(17):1598–1604PubMedCrossRef

Denham JW, Steigler A, Lamb DS et al (2005) Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: results from the Trans-Tasman Radiation Oncology Group 96.01 randomised controlled trial. Lancet Oncol 6(11):841–850PubMedCrossRef

Bolla M, Gonzalez D, Warde P et al (1997) Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337(5):295–300PubMedCrossRef

D’Amico AV, Manola J, Loffredo M et al (2004) 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 292(7):821–827CrossRef

Zelefsky MJ, Leibel SA, Gaudin PB et al (1998) Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41(3):491–500PubMedCrossRef

10.

Viani GA, Stefano EJ, Afonso SL (2009) Higher-than-conventional radiation doses in localized prostate cancer treatment: a meta-analysis of randomized, controlled trials. Int J Radiat Oncol Biol Phys 74(5):1405–1418PubMedCrossRef

11.

Roach M IIIrd, Hanks G, Thames H Jr et al (2006) Defining biochemical failure following radiotherapy with or without hormonal therpy in men with clinically localized prostate cancer. Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 65:965–974PubMedCrossRef

12.

Lee B, Shinohara K, Weinberg V et al (2007) Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 67(4):1106–1112PubMedCrossRef

13.

Nguyen PL, D’Amico AV, Lee AK, Suh WW (2007) Patient selection, cancer control, and complications after salvage local therapy for postradiation prostate-specific antigen failure: a systematic review of the literature. Cancer 110(7):1417–1428PubMedCrossRef

14.

Heidenreich A, Bastian PJ, Bellmunt J et al (2012) Guidelines on prostate cancer. European association of urology. http://www.uroweb.org/gls/pdf/08%20Prostate%20Cancer_LR%20March%2013th%202012.pdf

15.

Ryu S, Brown SL, Kim SH et al (1996) Preferential radiosensitization of human prostatic carcinoma cells by mild hyperthermia. Int J Radiat Oncol Biol Phys 34(1):133–138PubMedCrossRef

16.

Peschke P, Hahn EW, Wolber G et al (1996) Interstitial radiation and hyperthermia in the Dunning R3327 prostate tumour model: therapeutic efficacy depends on radiation dose-rate, sequence and frequency of heating. Int J Radiat Biol 70(5):609–616PubMedCrossRef

17.

Maluta S, Dall’Oglio S, Romano M et al (2007) Conformal radiotherapy plus local hyperthermia in patients affected by locally advanced high risk prostate cancer: preliminary results of a prospective phase II study. Int J Hyperthermia 23(5):451–456PubMedCrossRef

18.

Van Vulpen M, De Leeuw AA, Raaymakers BW et al (2004) Radiotherapy and hyperthermia in the treatment of patients with locally advanced prostate cancer: preliminary results. BJU Int 93(1):36–41CrossRef

19.

Tilly W, Gellermann J, Graf R et al (2005) Regional hyperthermia in conjunction with definitive radiotherapy against recurrent or locally advanced prostate cancer T3 pN0 M0. Strahlenther Onkol 181(1):35–41PubMedCrossRef

20.

Overgaard J, Gonzalez Gonzalez D, Hulshof MC et al (2009) Hyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic Oncology. 1996. Int J Hyperthermia 25(5):323–334PubMedCrossRef

21.

Vernon CC, Hand JW, Field SB et al (1996) Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys 35(4):731–744PubMedCrossRef

22.

Zee J van der, González González D, Rhoon GC van et al (2000) Comparison of radiotherapy alone with radiotherapy plus hyperthermia in locally advanced pelvic tumours: a prospective, randomised, multicentre trial. Dutch Deep Hyperthermia Group. Lancet 355(9210):1119–1125PubMedCrossRef

23.

Baronzio G, Gramaglia A, Fiorentini G (2009) Review. Current role and future perspectives of hyperthermia for prostate cancer treatment. In Vivo 23(1):143–146PubMed

24.

NCCN Clinical Practice Guidelines in Oncology (2012) Prostate cancer, version 1.2013. NCCN; 2012. http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf

25.

Bentzen S, Ritter MA (2005) The α/β ratio for prostate cancer: what is it, really? Radiother Oncol 76(1):1–3PubMedCrossRef

26.

Valdagni R, Nahum AE, Magnani T et al (2011) Long-term biochemical control of prostate cancer after standard or hyper-fractionation: evidence for different outcomes between low-intermediate and high risk patients. Radiother Oncol 101(3):454–459PubMedCrossRef

27.

Cheung R, Tucker SL, Lee AK et al (2005) Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 61(4):993–1002PubMedCrossRef

28.

Kovács G, Pötter R, Loch T et al (2005) GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. Radiother Oncol 74(2):137–148PubMedCrossRef

29.

Diaz A, Roach M IIIrd, Marquez C et al (1994) Indications for and the significance of seminal vesicle irradiation during 3D conformal radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 30(2):323–329PubMedCrossRef

30.

Makarov DV, Trock BJ, Humphreys EB et al (2007) Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69(6):1095–1101PubMedCrossRef

31.

http://www.rtog.org/CoreLab/ContouringAtlases/ProstatePelvicLymphNodes.aspx. Accessed 31 Dec 2012

32.

Van Vulpen M, De Leeuw JR, Van Gellekom MP et al (2003) A prospective quality of life study in patients with locally advanced prostate cancer, treated with radiotherapy with or without regional or interstitial hyperthermia. Int J Hyperthermia 19(4):402–413CrossRef

33.

Mohammed N, Ghilezan MI, Kestin L et al (2010) High dose rate re-irradiation with continuos hyperthermia for recurrent prostate cancer. Brachytherapy 9:S72CrossRef

34.

Williams V, Puthawala A, Phan TP et al (2007) Interstitial hyperthermia during HDR brachytherapy monotherapy for treatment of early stage prostate cancer with benign prostate hyperplasia. Brachytherapy 6:S86CrossRef

35.

Prionas SD, Kapp DS, Goffinet DR et al (1994) Thermometry of interstitial hyperthermia given as an adjuvant to brachytherapy for the treatment of carcinoma of the prostate. Int J Radiat Oncol Biol Phys 28(1):151–162PubMedCrossRef

36.

Sullivan L, Williams SG, Tai KH et al (2009) Urethral stricture following high dose rate brachytherapy for prostate cancer. Radiother Oncol 91:232–236PubMedCrossRef

37.

Khor R, Duchesne G, Tai KH et al (n d) Direct 2-arm comparison shows benefit of high-dose-rate brachytherapy boost vs external beam radiation therapy alone for prostate cancer. Int J Radiat Oncol Biol Phys (In Press Corrected Proof)

38.

Lettmaier S, Lotter M, Kreppner S et al (2012) Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer. Radiother Oncol 104(2):181–186. doi:10.1016/j.radonc.2012.07.003. (Epub 2012 Jul 30)PubMedCrossRef

39.

Van Vulpen M, De Leeuw AA, Van De Kamer JB et al (2003) Comparison of intra-luminal versus intra-tumoural temperature measurements in patients with locally advanced prostate cancer treated with the coaxial TEM system: report of a feasibility study. Int J Hyperthermia 19(5):481–497CrossRef

40.

41.

Hurwitz MD, Kaplan ID, Hansen JL et al (2005) Hyperthermia combined with radiation in treatment of locally advanced prostate cancer is associated with a favourable toxicity profile. Int J Hyperthermia 21(7):649–656PubMedCrossRef

42.

Hurwitz MD, Hansen JL, Prokopios-Davos S et al (2011) Hyperthermia combined with radiation for the treatment of locally advanced prostate cancer: long-term results from Dana-Farber Cancer Institute study 94–153. Cancer 117(3):510–516. doi:10.1002/cncr.25619PubMedCrossRef

43.

Kalapurakal JA, Mittal BB, Sathiaseelan V (2001) Re-irradiation and external hyperthermia in locally advanced, radiation recurrent, hormone refractory prostate cancer: a preliminary report. Br J Radiol 74(884):745–751PubMed

44.

Kalapurakal JA, Pierce M, Chen A, Sathiaseelan V (2003) Efficacy of irradiation and external hyperthermia in locally advanced, hormone-refractory or radiation recurrent prostate cancer: a preliminary report. Int J Radiat Oncol Biol Phys 57(3):654–664PubMedCrossRef

45.

Yamada Y, Rogers L, Demanes DJ et al (2012) American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherapy 11(1):20–32PubMedCrossRef

46.

Bruggmoser G, Bauchowitz S, Canters R et al (2011) Quality assurance for clinical studies in regional deep hyperthermia. Strahlenther Onkol 187(10):605–610PubMedCrossRef

Titel: Interstitial hyperthermia of the prostate in combination with brachytherapy
An evaluation of feasibility and early tolerance
verfasst von: A.M. Kukiełka, M.D.
M. Hetnał, M.D.
P. Brandys, M.D.
T. Walasek, M.D.
T. Dąbrowski, M.D.
E. Pluta, M.D.
D. Nahajowski
R. Kudzia
Publikationsdatum: 01.06.2013
Verlag: Springer-Verlag
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 6/2013
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-013-0321-6

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Interstitial hyperthermia of the prostate in combination with brachytherapy

An evaluation of feasibility and early tolerance